Switching JAK Inhibitors: Evaluating Baricitinib’s Effectiveness in Alopecia Areata After Tofacitinib Failure

    February 2025 in “ Archives of Dermatological Research ”
    Ala Ehsani, Zahra Razavi, Amirhossein Rahimnia … Hanie Babaie
    Studysummary This retrospective study observed that switching from tofacitinib to baricitinib improved hair growth in patients with alopecia areata, particularly for previous non-responders, and noted fewer side effects with baricitinib.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on link.springer.com →
    Discuss this study in the Community →

    Research cited in this study 13

    1. Deciphering the Complex Immunopathogenesis of Alopecia Areata International Journal of Molecular Sciences · 2024
    2. Exploring the Efficacy of Baricitinib in Treating Alopecia Areata After Failed Janus Kinase Inhibitor Therapy JAAD Case Reports · 2023
    3. Efficacy and Safety of Baricitinib in Patients With Alopecia Areata: Evidence to Date Drugs in context · 2023
    4. Alopecia Areata: Current Treatments and New Directions American Journal of Clinical Dermatology · 2023
    5. Efficacy and Safety of Different JAK Inhibitors in the Treatment of Alopecia Areata: A Network Meta-Analysis Frontiers in immunology · 2023
    6. Treatment of Moderate-to-Severe Alopecia Areata in Pre-Adolescent Children with Baricitinib British Journal of Dermatology · 2023
    7. Switching Between Tofacitinib and Baricitinib in Alopecia Areata: A Review of Clinical Response Journal of the American Academy of Dermatology · 2023
    8. Anxiety, Depression, and Quality of Life in Children and Adults With Alopecia Areata: A Systematic Review and Meta-Analysis Frontiers in Medicine · 2022
    9. Systematic Review: Alopecia Areata and Tofacitinib in Pediatric Patients Cutaneous and Ocular Toxicology · 2022
    10. Alopecia Areata: An Update on Etiopathogenesis, Diagnosis, and Management Clinical Reviews in Allergy & Immunology · 2021
    11. Benefit and Risk Profile of Tofacitinib for the Treatment of Alopecia Areata: A Systematic Review and Meta-Analysis Journal of the European Academy of Dermatology and Venereology · 2019
    12. JAK Inhibitors for Alopecia Areata: A Systematic Review and Meta-Analysis JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology · 2019
    13. Ruxolitinib for the Treatment of Severe Alopecia Areata Journal of the American Academy of Dermatology · 2018

    Related research 6

    1. Alopecia Universalis Treated With Tofacitinib: The Role of JAK/STAT Inhibitors in Hair Regrowth Cutis · 2023
    2. The Usefulness and Wellbeing of Tofacitinib in the Treatment of Alopecia Areata Journal of Armed Forces Medical College, Bangladesh · 2022
    3. Successful Treatment of Severe Alopecia Areata With Oral or Topical Tofacitinib PubMed · 2018
    4. Brazilian Experience of Treating Alopecia Universalis with Novel Antirheumatic Therapy Tofacitinib: A Case Series Rheumatology and Therapy · 2017
    5. Excellent Response to Tofacitinib Treatment in a Patient with Alopecia Universalis Acta dermatovenerologica Alpina, Pannonica et Adriatica (Tiskana izd.) · 2017
    6. Alopecia Areata Universalis in a Dog Veterinary dermatology · 2015